GE Healthcare Has Completed Recruitment In Its Phase 1 Program For A Manganese-Based Macrocyclic MRI Contrast Agent. This Manganese-Based Agent Could Provide A Potential Alternative Due To Perceived Concerns Relating To Gadolinium Retention
GE Healthcare Has Completed Recruitment In Its Phase 1 Program For A Manganese-Based Macrocyclic MRI Contrast Agent. This Manganese-Based Agent Could Provide A Potential Alternative Due To Perceived Concerns Relating To Gadolinium Retention
GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare's portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.
GE Healthcare 今天在奧地利維也納舉行的歐洲放射學大會（ECR）上宣布，完成第一期受試者的初期臨床開發計劃，以進行首個基於錳的大環磁共振成像（MRI）對比劑的初期臨床開發計劃。通常，MRI 試劑-用於增強異常結構或病變的可視化，並幫助健康和病理組織之間的區分-是基於的。這種基於錳的劑可以擴大 GE Healthcare 的 MRI 造影劑組合，可供放射科醫生使用，從而根據與保留有關的認知問題提供一種潛在的替代方案。
譯文內容由第三人軟體翻譯。